Tag: design

COMMUNIQUÉ DE PRESSE

Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.

Baltimore, MD, July 03, 2025 (GLOBE NEWSWIRE) -- As Washington debates the price tag of President Trump’s sweeping new economic agenda, a released presentation from former White House advisor Jim Rickards is drawing renewed attention to a vast—and long-overlooked—government-controlled asset.

Binaural beat-based audio suite supports focus, rest, and digital clarity with a non-invasive, non-clinical format—now updated for 2025.

Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

THE WOODLANDS, Texas, July 03, 2025 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 457 homes in June 2025 and closed 1,323 homes in the second quarter of 2025.

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

Now Reformulated With InnoSlim®, α-Lacys Reset®, and Capsimax® to Support Multi-Pathway Metabolic Function Without a Prescription